| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,166 |
| 2 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Lancet, The | 2012 | 2,743 |
| 3 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,819 |
| 4 | Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer | Journal of Experimental Medicine | 2017 | 1,720 |
| 5 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Cell | 2017 | 1,638 |
| 6 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | New England Journal of Medicine | 2019 | 1,479 |
| 7 | Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 | 1,398 |
| 8 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma | International Journal of Gynecological Cancer | 2021 | 1,012 |
| 9 | LincRNA-p21 Suppresses Target mRNA Translation | Molecular Cell | 2012 | 899 |
| 10 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C | Journal of Hepatology | 2013 | 839 |
| 11 | Cytokines in clinical cancer immunotherapy | British Journal of Cancer | 2019 | 809 |
| 12 | Advances in immunotherapy for hepatocellular carcinoma | Nature Reviews Gastroenterology and Hepatology | 2021 | 736 |
| 13 | Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis | International Journal of Radiation Oncology Biology Physics | 2013 | 562 |
| 14 | Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study | Radiotherapy and Oncology | 2016 | 546 |
| 15 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study | Annals of Oncology | 2019 | 520 |
| 16 | Immunological landscape and immunotherapy of hepatocellular carcinoma | Nature Reviews Gastroenterology and Hepatology | 2015 | 491 |
| 17 | Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma | Nature Medicine | 2019 | 488 |
| 18 | CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity | Immunity | 2020 | 444 |
| 19 | Epigenetic regulation of microRNA expression in colorectal cancer | International Journal of Cancer | 2009 | 422 |
| 20 | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence | 2022 | 405 |
| 21 | Classification of current anticancer immunotherapies | Oncotarget | 2014 | 404 |
| 22 | Direct Effects of Type I Interferons on Cells of the Immune System | Clinical Cancer Research | 2011 | 402 |
| 23 | T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy | Cancer Discovery | 2014 | 377 |
| 24 | A benchmark for comparison of cell tracking algorithms | Bioinformatics | 2014 | 353 |
| 25 | Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients | Annals of Oncology | 2017 | 346 |
| 26 | Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect | Trends in Immunology | 2018 | 343 |
| 27 | Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy | Nature | 2019 | 339 |
| 28 | Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors | Nature Medicine | 2020 | 334 |
| 29 | Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2021 | 264 |
| 30 | Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia | Nature Genetics | 2007 | 254 |
| 31 | Intratumoural administration and tumour tissue targeting of cancer immunotherapies | Nature Reviews Clinical Oncology | 2021 | 253 |
| 32 | MicroRNA-451 Is Involved in the Self-renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells | Stem Cells | 2011 | 249 |
| 33 | Systemic treatment of hepatocellular carcinoma: An EASL position paper | Journal of Hepatology | 2021 | 249 |
| 34 | Education, implementation, and policy barriers to greater integration of palliative care: A literature review | Palliative Medicine | 2016 | 248 |
| 35 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target | Molecular Cancer | 2018 | 248 |
| 36 | Prognostic factors and prevention of radioembolization-induced liver disease | Hepatology | 2013 | 245 |
| 37 | Immunological impact of cell death signaling driven by radiation on the tumor microenvironment | Nature Immunology | 2020 | 240 |
| 38 | MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo | Cancer Cell | 2012 | 239 |
| 39 | Alternative splicing: an emerging topic in molecular and clinical oncology | Lancet Oncology, The | 2007 | 232 |
| 40 | Paradigms on Immunotherapy Combinations with Chemotherapy | Cancer Discovery | 2021 | 232 |
| 41 | Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas | Blood | 2007 | 229 |
| 42 | Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines | Human Mutation | 2008 | 227 |
| 43 | Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression | Journal of Immunology | 2012 | 227 |
| 44 | Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study | Lancet Oncology, The | 2021 | 226 |
| 45 | Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma | New England Journal of Medicine | 2022 | 223 |
| 46 | IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy | Nature | 2020 | 219 |
| 47 | Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study | Annals of Oncology | 2017 | 215 |
| 48 | Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins | Clinical Cancer Research | 2014 | 212 |
| 49 | The forefront of ovarian cancer therapy: update on PARP inhibitors | Annals of Oncology | 2020 | 212 |
| 50 | Radiation effects on antitumor immune responses: current perspectives and challenges | Therapeutic Advances in Medical Oncology | 2018 | 198 |
